Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2018

View Archived Issues

From Adam's rib to Miss Piggy's jaw

Separating the good, the bad and the indifferent in neurodegeneration

Cell therapies wake up and smell the coffee

Nipro applies for approval of human stem cell therapy product for spinal cord injury

Gazyva receives approval in Japan

Bacteriophages adjuvant therapy tested in patients with severe staphylococcal sepsis

Cereno reports results from first clinical study of CS-1

Ocugen initiates first pivotal trial of OCU-300 for ocular graft-versus-host disease

FDA awards regenerative medicine advanced therapy designation to romyelocel-L

FDA grants fast track designation to CUTX-101 for treatment of classic Menkes disease

Compugen announces IND clearances for BAY-1905254 and COM-701

Phase I/II data presented for FT-2102, a mutant IDH1 inhibitor, in AML or MDS patients

Advicenne reports preliminary phase III extension study results for ADV-7103

TRIGR Therapeutics and ABL Bio collaborate in immuno-oncology

Topline data reported from phase IIa trial of IRL-752 in Parkinson's disease dementia

Dafclir receives approval in Japan

Glactone Pharma Development patents STAT3 inhibitors

Entyvio approved in Japan for ulcerative colitis

NovaTarg divulges new AMPK activators for diabetes

FDA grants priority review to sBLA for Keytruda with chemotherapy in first-line metastatic NSCLC

Merck & Co. presents FFA1 receptor agonists

Neovacs reports phase IIb results for IFN-alpha kinoid in moderate to severe lupus

University of Texas System synthesizes MAP3K12 inhibitors

FDA approves Aristada Initio

Xenon Pharmaceuticals divulges Nav1.6 channel blockers

AzurRx completes phase IIa study of MS-1819-SD in exocrine pancreatic insufficiency

Tafinlar and Mekinist approved in Japan as adjuvant therapy for BRAF mutation-positive melanoma

Introducing BioWorld Science: supporting R&D decisions through drug discovery and preclinical news

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Pharma industry faces long haul to get return on investment from AI
BioWorld Science
Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on...